Proteomics: Applications and opportunities in preclinical drug development

Sandra Steiner, Frank A. Witzmann

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

Advances in DNA sequencing and the near-term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public domain, demonstrate the potential of proteomics in the preclinical phases of pharmaceutical development. Over the next few years, it is anticipated that functional genomics and proteomics will have major impacts on the clinical phases of drug development. Expected benefits are earlier proof-of-concept studies in man and increased efficiency of clinical trials through the availability of biologically relevant markers for drug efficacy and safety.

Original languageEnglish (US)
Pages (from-to)2099-2104
Number of pages6
JournalELECTROPHORESIS
Volume21
Issue number11
DOIs
StatePublished - Jul 17 2000

Keywords

  • Functional genomics
  • Mass spectrometry
  • Pharmaceutical development
  • Proteomics
  • Review
  • Two-dimensional electrophoresis

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Proteomics: Applications and opportunities in preclinical drug development'. Together they form a unique fingerprint.

  • Cite this